Chromogranin a cells in the stomachs of patients with sporadic irritable bowel syndrome

Molecular Medicine Reports

Volumn 10, Issue 4, 2014, Pages 1753-1757

  El Salhy, Magdy ^a,b   Gilja, Odd Helge ^b   Hausken, Trygve ^b  

^a Stord Hospital   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Computer image analysis; Endocrine cells; Immunohistochemistry; Immunoreactivity intensity

Indexed keywords

CHROMOGRANIN A;

ADOLESCENT; ADULT; DUODENUM; ENDOCRINE CELL; ESOPHAGUS; FEMALE; GASTROSCOPY; HUMAN; IMMUNOHISTOCHEMISTRY; IRRITABLE COLON; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH; YOUNG ADULT;

ADOLESCENT; ADULT; CHROMOGRANIN A; DUODENUM; ENDOCRINE CELLS; ESOPHAGUS; FEMALE; GASTROSCOPY; HUMANS; IMMUNOHISTOCHEMISTRY; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; STOMACH; YOUNG ADULT;

EID: 84924219726     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2472     Document Type: Article

References (32)

1. El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T (eds): Irritable Bowel Syndrome: Diagnosis, Pathogenesis and Treatment Options. Nova Science Publishers, Inc., New York, NY, 2012.
2. Spiller RC: Potential biomarkers. Gastroenterol Clin North Am 40: 121-139, 2011.
3. Spiller R, Aziz Q, Creed F, et al; Clinical Services Committee of The British Society of Gastroenterology: Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56: 1770-1798, 2007. (Pubitemid 350206308)
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F and Spiller RC: Functional bowel disorders. Gastroenterology 130: 1480-1491, 2006.
5. Drossman DA, Li Z, Andruzzi E, et al: U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 38: 1569-1580, 1993. (Pubitemid 23271409)
6. Thompson WG: A world view of IBS. In: Irritable bowel syndrome: diagnosis and treatment. Camilleri M and Spiller RC (eds.) Saunders, Philadelphia, pp 17-26, 2002.
7. Harvey RF, Mauad EC and Brown AM: Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1: 963-965, 1987. (Pubitemid 17055976)
8. Nørgaard M, Farkas DK, Pedersen L, et al: Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study. Br J Cancer 104: 1202-1206, 2011.
9. Taupenot L, Harper KL and O'Connor DT: The chromogranin-secretogranin family. N Engl J Med 348: 1134-1149, 2003. (Pubitemid 36337325)
10. Wiedenmann B and Huttner WB: Synaptophysin and chromogranins/ secretogranins - widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol 58: 95-121, 1989. (Pubitemid 20012954)
11. Deftos LJ: Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 12: 181-187, 1991.
12. El-Salhy M, Lomholt-Beck B and Hausken T: Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol 45: 1435-1439, 2010.
13. El-Salhy M, Mazzawi T, Gundersen D and Hausken T: Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. Mol Med Report 6: 1223-1225, 2012.
14. El-Salhy M, Wendelbo IH and Gundersen D: Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome. Mol Med Rep 7: 1241-1244, 2013.
15. El-Salhy M, Seim I, Chopin L, Gundersen D, Hatlebakk JG and Hausken T: Irritable bowel syndrome: the role of gut neuroendocrine peptides. Front Biosci (Elite Ed) 4: 2783-2800, 2012.
16. El-Salhy M, Ostgaard H, Gundersen D, Hatlebakk JG and Hausken T: The role of diet in the pathogenesis and management of irritable bowel syndrome (Review). Int J Mol Med 29: 723-731, 2012.
17. El-Salhy M and Mahdavi J: Image analysis of the duodenal endocrine cells in mice with particular regard to optic densitomertry. Uppsala J Med Sci 102: 175-184, 1997. (Pubitemid 127518079)
18. El-Salhy M: Ghrelin in gastrointestinal diseases and disorders: a possible role in the pathophysiology and clinical implications (review). Int J Mol Med 24: 727-732, 2009.
19. El-Salhy M, Lillebø E, Reinemo A and Salmelid L: Ghrelin in patients with irritable bowel syndrome. Int J Mol Med 23: 703-707, 2009.
20. Dizdar V, Spiller R, Singh G, et al: Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 31: 883-891, 2010.
21. El-Salhy M, Vaali K, Dizdar V and Hausken T: Abnormal small-intestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci 55: 3508-3513, 2010.
22. El-Salhy M, Gundersen D, Ostgaard H, Lomholt-Beck B, Hatlebakk JG and Hausken T: Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci 57: 873-878, 2012.
23. El-Salhy M, Gundersen D, Hatlebakk JG, Gilja OH and Hausken T: Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regul Pept 188: 60-65, 2014.
24. Coates MD, Mahoney CR, Linden DR, et al: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126: 1657-1664, 2004. (Pubitemid 38736329)
25. Wang SH, Dong L, Luo JY, et al: Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol 13: 6041-6047, 2007. (Pubitemid 350238273)
26. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK and Cho SW: The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 23: 1689-1694, 2008.
27. Park JH, Rhee PL, Kim G, et al: Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil 18: 539-546, 2006. (Pubitemid 43855807)
28. Kim HS, Lim JH, Park H and Lee SI: Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection - an observation in a small case control study. Yonsei Med J 51: 45-51, 2010.
29. Dunlop SP, Coleman NS, Blackshaw E, et al: Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 3: 349-357, 2005. (Pubitemid 40488343)
30. Spiller RC, Jenkins D, Thornley JP, et al: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47: 804-811, 2000.
31. Wang LH, Fang XC and Pan GZ: Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 53: 1096-1101, 2004.
32. Dunlop SP, Jenkins D, Neal KR and Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125: 1651-1659, 2003. (Pubitemid 37500429)